---
title: "Sangamo Therapeutics files for Chapter 11 as Lilly, Astellas anchor asset sale bids"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290560244.md"
description: "Sangamo Therapeutics filed for Chapter 11 bankruptcy protection, initiating a court-supervised asset auction under Section 363. Eli Lilly and Astellas have secured stalking-horse bids for key programs, including ST-506 and ST-920 respectively. Northridge ATM committed to DIP financing to support operations during the process, subject to court approval."
datetime: "2026-06-23T12:05:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290560244.md)
  - [en](https://longbridge.com/en/news/290560244.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290560244.md)
---

# Sangamo Therapeutics files for Chapter 11 as Lilly, Astellas anchor asset sale bids

-   Sangamo Therapeutics filed for voluntary Chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. \* Process targets a court-supervised auction of substantially all assets, with sales expected to run under Section 363. \* Lilly signed a stalking-horse deal for key technology platforms and the ST-506 prion disease program. \* Astellas signed a stalking-horse deal for the ST-920 Fabry disease gene therapy program. \* DIP financing commitment secured from Northridge ATM to support operations during the Chapter 11 process, subject to court approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230805PRIMZONEFULLFEED9751019) on June 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [SGMO.US](https://longbridge.com/en/quote/SGMO.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [ALPMY.US](https://longbridge.com/en/quote/ALPMY.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [SGMOQ.US](https://longbridge.com/en/quote/SGMOQ.US.md)
- [4503.JP](https://longbridge.com/en/quote/4503.JP.md)

## Related News & Research

- [Eli Lilly Stock: Analyst Estimates & Ratings](https://longbridge.com/en/news/295090195.md)
- [LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs](https://longbridge.com/en/news/295005008.md)
- [Sarasin & Partners LLP Sells 11,349 Shares of Eli Lilly and Company $LLY](https://longbridge.com/en/news/295214848.md)
- [LLY: Q2 2026 revenue surged 48% to $23B, driving raised full-year guidance and robust pipeline progress](https://longbridge.com/en/news/294955478.md)
- [Eli Lilly and Company (NYSE:LLY) Releases Quarterly Earnings Results, Beats Expectations By $2.32 EPS](https://longbridge.com/en/news/295054597.md)